Stereotaxis Inc STXS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if STXS is a good fit for your portfolio.
News
-
Stereotaxis to Report First Quarter 2024 Financial Results on May 13, 2024
-
Stereotaxis Announces Regulatory Submissions of the MAGiC Ablation Catheter in Europe and the United States
-
Stereotaxis Reports 2023 Full Year Financial Results
-
Intermountain Health Extends Leadership in Heart Care with Adoption of Advanced Robotic Technology
-
Stereotaxis to Report Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024
Trading Information
- Previous Close Price
- $2.38
- Day Range
- $2.26–2.40
- 52-Week Range
- $1.33–3.29
- Bid/Ask
- $2.36 / $3.25
- Market Cap
- $193.00 Mil
- Volume/Avg
- 481,995 / 328,335
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 7.17
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems; Disposables, Royalty; and Sublease, of which a majority of revenue is generated from the Disposables, service and accessories stream. The company generates the majority of revenue from the United States.
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Stock Style Box
- Small Value
- Total Number of Employees
- 122
- Website
- https://www.stereotaxis.com
Competitors
Valuation
|
Metric
|
STXS
|
ISRG
|
|---|---|---|
Price/Earnings (Normalized) | — | 62.71 |
Price/Book Value | 11.79 | 9.53 |
Price/Sales | 7.17 | 18.37 |
Price/Cash Flow | — | 48.33 |
Price/Earnings
STXS
ISRG
Financial Strength
|
Metric
|
STXS
|
ISRG
|
|---|---|---|
Quick Ratio | 1.78 | 3.91 |
Current Ratio | 2.51 | 4.76 |
Interest Coverage | — | — |
Quick Ratio
STXS
ISRG
Profitability
|
Metric
|
STXS
|
ISRG
|
|---|---|---|
Return on Assets (Normalized) | −21.12% | 14.56% |
Return on Equity (Normalized) | −47.38% | 17.02% |
Return on Invested Capital (Normalized) | −34.36% | 15.43% |
Return on Assets
STXS
ISRG
Medical Instruments & Supplies Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ISRG
| Intuitive Surgical Inc | Gwvjrbmjty | Bxx | $133.8 Bil | |
BDX
| Becton Dickinson & Co | Vnhqnqjmt | Brldjf | $67.6 Bil | |
ALC
| Alcon Inc | Lbsnjnh | Pklqrf | $39.1 Bil | |
CLPBY
| Coloplast A/S ADR | Dwmpjstjy | Fltg | $29.7 Bil | |
WST
| West Pharmaceutical Services Inc | Ghdvrrrzjh | Hjnk | $28.6 Bil | |
RMD
| ResMed Inc | Zmvkxmtfy | Hfszrs | $27.0 Bil | |
BAX
| Baxter International Inc | Jsfbpmdz | Tgszsr | $20.9 Bil | |
COO
| The Cooper Companies Inc | Xdjbnccd | Jzpsb | $18.2 Bil | |
HOLX
| Hologic Inc | Jzjkvvqk | Tccwmgp | $17.9 Bil | |
TFX
| Teleflex Inc | Whr | Nyv | $9.9 Bil |